Pharma BD Deal Intelligence
A small drug-discovery-tech tuck-in that got absorbed and then erased when its acquirer itself was acquired four years later
Full analysis, sources & comparables →Schering-Plough sought to 'improve its drug discovery technology and establish a beachhead in the fertile Cambridge biotechnology cluster.'
Fred Hassan, Chairman and CEO, Schering-Plough: 'This acquisition will further strengthen the discovery capabilities of Schering-Plough and is another…
Fred Hassan served as Final CEO & Chairman of Schering-Plough from April 2003 to November 3, 2009, when Schering-Plough merged with Merck & Co.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Schering-Plough acquires most assets of NeoGenesis Pharmaceuticals (chemistry/discovery platform). February 2005.
A small drug-discovery-tech tuck-in that got absorbed and then erased when its acquirer itself was acquired four years later
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering-Plough Corp. / NeoGenesis Pharmaceuticals (this deal) | 2005 | — | 30 |
| Schering-Plough Corp. / Organon International | 2007 | $14.4B | 56 |
| Schering-Plough Corp. / Organon & Co. | 2007 | $14.4B | 48 |
| Schering-Plough Corp. / Organon BioSciences N.V. (Akzo Nobel) | 2007 | $14.5B | 48 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |